Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the First-Line Treatment for Pancreatic Cancer: A Systematic Review and Meta-Analysis Article (Faculty180)

cited authors

  • Merza, Nooraldin; Farooqui, Sabeeh K; Dar, Sop H; Varughese, Tony; Awan, Rehmat U; Qureshi, Lamaan; Ansari, S A; Qureshi, Hadi; Mcilvaine, Jamie; Vohra, Ishaan; Nawras, Yusuf; Kobeissy, Abdallah; Hassan, Mona

description

  • The efficacy and safety of Folfirinox (FFX) or gemcitabine + nab-paclitaxel (GnP) to be used as the first-line drugs for pancreatic cancer (PC) is yet to be established. We conducted an analysis of retrospective studies to assess the efficacy and safety of these two regimens by comparing their survival and safety outcomes in patients with PC.

authors

publication date

  • 2023

published in

start page

  • 325

end page

  • 339

volume

  • 14